The HDACi vorinostat reverses lenvatinib resistance by suppressing AKT activation, while co-treatment with lenvatinib and AKT/HDACi synergistically induces HCC cell apoptosis [188]. Here, AKT1 is linked to hepatocellular carcinoma.